Pharmacological approach for drug repositioning against cardiorenal diseases

Journal of Medical Investigation

Volumn 64, Issue 3-4, 2017, Pages 197-201

  Zamami, Yoshito ^a,b   Imanishi, Masaki ^b   Takechi, Kenshi ^b   Ishizawa, Keisuke ^a,b  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cardiorenal diseases; Drug repositioning; Pharmacology

Indexed keywords

ACETOPHENAZINE; ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR ALPHA; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; DUTASTERIDE; IBUDILAST; NIFEDIPINE; NITROSONIFEDIPINE; OLMESARTAN; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE; RIBAVIRIN; TAMOXIFEN; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CELL PROTECTION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG REPOSITIONING; DRUG SAFETY; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY CELL; KIDNEY DISEASE; NONHUMAN; OXIDATIVE STRESS; RENAL PROTECTION; REVIEW; CHRONIC KIDNEY FAILURE; METABOLISM;

ANGIOTENSIN RECEPTOR ANTAGONISTS; CARDIOVASCULAR DISEASES; DRUG REPOSITIONING; HUMANS; INSULIN RESISTANCE; REACTIVE OXYGEN SPECIES; RENAL INSUFFICIENCY, CHRONIC; THIAZOLIDINEDIONES;

EID: 85030251016     PISSN: 13431420     EISSN: 13496867     Source Type: Journal    
DOI: 10.2152/jmi.64.197     Document Type: Review

References (36)

1. Ashburn TT, Thor KB: Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3: 673- 683, 2004
2. Langedijk J, Mantel - Teeuwisse AK, Slijkerman DS, Schutjens MH: Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today 20: 1027- 1034, 2015
3. Ferreira LG, Andricopulo AD: 33. Drug repositioning approaches to parasitic diseases: a medicinal chemistry perspective. Drug Discov Today 21: 1699- 1710, 2016
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: 33. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296- 1305, 2004
5. Bauer V, Rekalov VV, Juranek I, Gergel D, Bohov P: Effect of illuminated nifedipine, a potent antioxidant, on intestinal and vascular smooth muscles. British journal of pharmacology 115: 871- 874, 1995
6. Ohkubo T, Noro H, Sugawara K: High- performance liquid chromatographic determination of nifedipine and a trace photodegradation product in hospital prescriptions. Journal of pharmaceutical and biomedical analysis 10: 67- 70, 1992
7. Stasko A, Brezova V, Biskupic S, Ondrias K, Misik V: Reactive radical intermediates formed from illuminated nifedipine. Free radical biology & medicine 17: 545- 556, 1994
8. Horinouchi Y, Tsuchiya K, Taoka C, Tajima S, Kihira Y, Matsuda Y, Shishido K, Yoshida M, Hamano S, Kawazoe K, Ikeda Y, Ishizawa K, Tomita S, Tamaki T: Antioxidant effects of photodegradation product of nifedipine. Chem Pharm Bull (Tokyo) 59: 208- 214, 2011
9. Fukuhara Y, Tsuchiya K, Horinouchi Y, Tajima S, Kihira Y, Hamano S, Kawazoe K, Ikeda Y, Ishizawa K, Tomita S, Tamaki T: Protective effect of photodegradation product of nifedipine against tumor necrosis factor alpha- induced oxidative stress in human glomerular endothelial cells. The journal of medical investigation: JMI 58: 118- 126, 2011
10. Ishizawa K, Yamaguchi K, Horinouchi Y, Fukuhara Y, Tajima S, Hamano S, Tomita S, Tsuchiya K, Tamaki T: Drug discovery for overcoming chronic kidney disease (CKD): development of drugs on endothelial cell protection for overcoming CKD. Journal of pharmacological sciences 109: 14- 19, 2009
11. Sakurada T, Ishizawa K, Imanishi M, Izawa- Ishizawa Y, Fujii S, Tominaga E, Tsuneishi T, Horinouchi Y, Kihira Y, Ikeda Y, Tomita S, Aihara K, Minakuchi K, Tsuchiya K, Tamaki T: Nitrosonifedipine ameliorates angiotensin II- induced vascular remodeling via antioxidative effects. Naunyn- Schmiedeberg’s archives of pharmacology 386: 29- 39, 2013
12. Ishizawa K, Izawa- Ishizawa Y, Yamano N, Urushihara M, Sakurada T, Imanishi M, Fujii S, Nuno A, Miyamoto L, Kihira Y, Ikeda Y, Kagami S, Kobori H, Tsuchiya K, Tamaki T: Nitrosonifedipine ameliorates the progression of type 2 diabetic nephropathy by exerting antioxidative effects. PLoS One 9: e 86335, 2014
13. Viberti G, Wheeldon NM: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure- independent effect. Circulation 106: 672- 678, 2002
14. Parving HH, Lehnert H, Brochner- Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870- 878, 2001
15. Ogawa S, Mori T, Nako K, Kato T, Takeuchi K, Ito S: Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 47: 699- 705, 2006
16. Akishita M, Nagai K, Xi H, Yu W, Sudoh N, Watanabe T, Ohara- Imaizumi M, Nagamatsu S, Kozaki K, Horiuchi M, Toba K: Renin- angiotensin system modulates oxidative stress-induced endothelial cell apoptosis in rats. Hypertension 45: 1188- 1193, 2005
17. Shao J, Nangaku M, Inagi R, Kato H, Miyata T, Matsusaka T, Noiri E, Fujita T: Receptor- independent intracellular radical scavenging activity of an angiotensin II receptor blocker. J Hypertens 25: 1643- 1649, 2007
18. Cianchetti S, Del Fiorentino A, Colognato R, Di Stefano R, Franzoni F, Pedrinelli R: Anti - inflammatory and anti - oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 198: 22- 28, 2008
19. Ishizawa K, Izawa- Ishizawa Y, Dorjsuren N, Miki E, Kihira Y, Ikeda Y, Hamano S, Kawazoe K, Minakuchi K, Tomita S, Tsuchiya K, Tamaki T: Angiotensin II receptor blocker attenuates PDGF- induced mesangial cell migration in a receptor-independent manner. Nephrol Dial Transplant 25: 364- 372, 2010
20. Izawa- Ishizawa Y, Ishizawa K, Sakurada T, Imanishi M, Miyamoto L, Fujii S, Taira H, Kihira Y, Ikeda Y, Hamano S, Tomita S, Tsuchiya K, Tamaki T: Angiotensin II receptor blocker improves tumor necrosis factor- alpha- induced cytotoxicity via antioxidative effect in human glomerular endothelial cells. Pharmacology 90: 324- 331, 2012
21. Zhang HY, Reddy SR, Kotchen TA: Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity. Hypertension 24: 106- 110, 1994
22. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK, Hsueh WA: Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 96: 354- 360, 1995
23. Grinsell JW, Lardinois CK, Swislocki A, Gonzalez R, Sare JS, Michaels JR, Starich GH: Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat. Am J Hypertens 13: 370- 375, 2000
24. Takatori S, Mizote M, Zamami Y, Kurosaki Y, Kawasaki H: Effects of insulin on vascular responses to spinal cord stimulation and vasoactive agents in pithed rats. Br J Pharmacol 140: 1137- 1145, 2003
25. Zamami Y, Takatori S, Yamawaki K, Miyashita S, Mio M, Kitamura Y, Kawasaki H: Acute hyperglycemia and hyperinsulinemia enhance adrenergic vasoconstriction and decrease calcitonin gene- related peptide- containing nerve- mediated vasodilation in pithed rats. Hypertens Res 31: 1033- 1044, 2008
26. Takatori S, Zamami Y, Mio M, Kurosaki Y, Kawasaki H: Chronic hyperinsulinemia enhances adrenergic vasoconstriction and decreases calcitonin gene- related peptide- containing nerve- mediated vasodilation in pithed rats. P Hypertens Res 29: 361- 368, 2006
27. Zamami Y, Takatori S, Goda M, Koyama T, Iwatani Y, Jin X, Takai - Doi S, Kawasaki H: Royal jelly ameliorates insulin resistance in fructose- drinking rats. Biol Pharm Bull 31: 2103-2107, 2008
28. Zamami Y, Takatori S, Hobara N, Yabumae N, Tangsucharit P, Jin X, Hashikawa N, Kitamura Y, Sasaki K, Kawasaki H: Hyperinsulinemia induces hypertension associated with neurogenic vascular dysfunction resulting from abnormal perivas-cular innervations in rat mesenteric resistance arteries. Hypertens Res 34: 1190- 1196, 2011
29. Takatori S, Zamami Y, Hashikawa- Hobara N, Kawasaki H: Insulin resistance- induced hypertension and a role of perivas-cular CGRPergic nerves. Curr Protein Pept Sci 14: 275- 281, 2013
30. Takatori S, Zamami Y, Yabumae N, Hanafusa N, Mio M, Egawa T, Kawasaki H: Pioglitazone opposes neurogenic vascular dysfunction associated with chronic hyperinsulinaemia. Br J Pharmacol 153: 1388- 1398, 2008
31. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang AP, Morgan AA, Sarwal MM, Pasricha PJ, Butte AJ: Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 3: 96ra76, 2011
32. Zhao S, Nishimura T, Chen Y, Azeloglu EU, Gottesman O, Giannarelli C, Zafar MU, Benard L, Badimon JJ, Hajjar RJ, Goldfarb J, Iyengar R: Systems pharmacology of adverse event mitigation by drug combinations. Sci Transl Med 5: 206ra140, 2013
33. Gibson CC, Zhu W, Davis CT, Bowman- Kirigin JA, Chan AC, Ling J, Walker AE, Goitre L, Delle Monache S, Retta SF, Shiu YT, Grossmann AH, Thomas KR, Donato AJ, Lesniewski LA, Whitehead KJ, Li DY: Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation. Circulation 131: 289- 299, 2015
34. Ghosh CC, Thamm K, Berghelli AV, Schrimpf C, Maski MR, Abid T, Milam KE, Rajakumar A, Santel A, Kielstein JT, Ahmed A, Thickett D, Wang K, Chase M, Donnino MW, Aird WC, Haller H, David S, Parikh SM: Drug Repurposing Screen Identifies Foxo1- Dependent Angiopoietin- 2 Regulation in Sepsis. Crit Care Med 43: e230- 40, 2015
35. Wang K, Wan M, Wang RS, Weng Z: Opportunities for Web-based Drug Repositioning: Searching for Potential Antihypertensive Agents with Hypotension Adverse Events. J Med Internet Res 18: e76, 2016
36. Naoya Hashikawa, Yuta Utaka, Takumi Ogawa, Ryo Tanoue, Yuna Morita, Sayumi Yamamoto, Satoru Yamaguchi, Masafumi Kayano, Yoshito Zamami, Narumi Hashikawa- Hobara: HSP 105 prevents depression- like behavior by increasing hippocampal brain- derived neurotrophic factor levels in mice. Sci Adv 3: e1603014, 2017